Cargando…

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program

OBJECTIVE: Patients with lipodystrophy have severe metabolic abnormalities (insulin resistance, diabetes, and hypertriglyceridemia) that may increase morbidity and mortality. Metreleptin is approved by the United States Food and Drug Administration for treatment of generalized forms of lipodystrophy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ajluni, Nevin, Dar, Moahad, Xu, John, Neidert, Adam H, Oral, Elif A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026130/ https://www.ncbi.nlm.nih.gov/pubmed/27642538 http://dx.doi.org/10.4172/2155-6156.1000659

Ejemplares similares

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants
por: Eldin, Abdelwahab J., et al.
Publicado: (2018)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

New advances in the treatment of generalized lipodystrophy: role of metreleptin
por: Rodriguez, Alexander J, et al.
Publicado: (2015)

PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy
por: Akinci, Efe Y, et al.
Publicado: (2021)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
por: Schweisberger, Cintya, et al.
Publicado: (2021)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
por: Chiquette, Elaine, et al.
Publicado: (2017)

RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance
por: Lambadiari, Vaia, et al.
Publicado: (2021)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network
por: Mosbah, Héléna, et al.
Publicado: (2022)

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

SAT-622 Heterogeneity of Familial Partial Lipodystrophy Type 2 from a Genotype-Phenotype Perspective
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2020)

MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
por: Haymond, Morey W, et al.
Publicado: (2023)

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis
por: Cook, Keziah, et al.
Publicado: (2021)

Body Composition And Bone Mineral Differences According to Lamin A (LMNA) Genotype in Familial Partial Lipodystrophy Type 2
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports
por: Shibata, Yusuke, et al.
Publicado: (2018)

Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People
por: Özen, Samim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9rjhk0d12j8qogmvhqma8e0ft